Logotype for Elementis plc

Elementis (ELM) H2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Elementis plc

H2 2025 earnings summary

5 Mar, 2026

Executive summary

  • Achieved strong profit growth and margin expansion despite a soft demand environment and slight revenue decline, demonstrating business resilience and quality.

  • Completed strategic divestments of Talc and Chromium, transforming into a pure-play specialty chemicals business focused on personal care and coatings, and acquired Alchemy Ingredients.

  • Announced sale of the pharmaceutical business to ABF for ~$40m, further sharpening strategic focus and expected to uplift 2025 group operating margins.

  • Launched the Elevate Elementis strategy, targeting mid-single-digit revenue growth, >23% operating margins, and >90% three-year operating cash conversion, with innovation sales rising to 16.4%.

  • Achieved zero lost time accidents and significantly reduced carbon footprint by nearly 80% since 2019, including a 77% reduction in carbon intensity.

Financial highlights

  • Adjusted operating profit grew 4.6% to $126.7 million, with a 150 basis point margin improvement to 21.2%.

  • Adjusted EPS increased 14.2% to $0.137, aided by lower net finance costs and share buyback.

  • Group revenue declined 1.9% year-over-year to $597.5 million, with coatings volumes down but personal care volumes up.

  • Free cash flow was $41 million, down from $51 million, due to working capital outflow and higher CapEx.

  • Net debt ended at $185.4 million, with net debt/EBITDA at 1.3x after acquisitions and shareholder returns.

Outlook and guidance

  • Confident in delivering organic growth through R&D, customer intimacy, best-in-class service, and operational efficiency in 2026.

  • New mid-term targets: mid-single-digit revenue growth, operating margin above 23%, operating cash conversion above 90%, and ROCE above 30%.

  • 2026 guidance: capex at 4-5% of revenue, net finance costs ~$20m, effective tax rate ~25%.

  • Board recommended a final dividend of GBP 0.03, full year up 7.5% to GBP 0.043 (31% payout ratio).

  • Proceeds from pharma business sale expected to be distributed to shareholders upon completion.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more